NanoViricides (NNVC) Competitors $1.42 +0.03 (+1.79%) As of 10:40 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NNVC vs. IMUX, ABOS, EPIX, CELU, OKYO, PLRX, LIMN, ELUT, ENTX, and ORMPShould you be buying NanoViricides stock or one of its competitors? The main competitors of NanoViricides include Immunic (IMUX), Acumen Pharmaceuticals (ABOS), ESSA Pharma (EPIX), Celularity (CELU), OKYO Pharma (OKYO), Pliant Therapeutics (PLRX), Liminatus Pharma (LIMN), Elutia (ELUT), Entera Bio (ENTX), and Oramed Pharmaceuticals (ORMP). These companies are all part of the "pharmaceutical products" industry. NanoViricides vs. Its Competitors Immunic Acumen Pharmaceuticals ESSA Pharma Celularity OKYO Pharma Pliant Therapeutics Liminatus Pharma Elutia Entera Bio Oramed Pharmaceuticals Immunic (NASDAQ:IMUX) and NanoViricides (NYSE:NNVC) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, media sentiment, valuation and risk. Which has more risk and volatility, IMUX or NNVC? Immunic has a beta of 1.44, meaning that its share price is 44% more volatile than the S&P 500. Comparatively, NanoViricides has a beta of 1.15, meaning that its share price is 15% more volatile than the S&P 500. Is IMUX or NNVC more profitable? NanoViricides' return on equity of -87.90% beat Immunic's return on equity.Company Net Margins Return on Equity Return on Assets ImmunicN/A -461.46% -217.16% NanoViricides N/A -87.90%-78.69% Which has preferable earnings & valuation, IMUX or NNVC? NanoViricides is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmunicN/AN/A-$100.51M-$1.23-0.66NanoViricidesN/AN/A-$8.29M-$0.70-2.04 Does the media refer more to IMUX or NNVC? In the previous week, Immunic and Immunic both had 1 articles in the media. Immunic's average media sentiment score of 0.96 beat NanoViricides' score of 0.15 indicating that Immunic is being referred to more favorably in the media. Company Overall Sentiment Immunic Positive NanoViricides Neutral Do analysts rate IMUX or NNVC? Immunic currently has a consensus target price of $7.50, suggesting a potential upside of 830.52%. Given Immunic's stronger consensus rating and higher possible upside, research analysts plainly believe Immunic is more favorable than NanoViricides.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immunic 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29NanoViricides 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do insiders & institutionals hold more shares of IMUX or NNVC? 51.8% of Immunic shares are owned by institutional investors. Comparatively, 10.3% of NanoViricides shares are owned by institutional investors. 4.6% of Immunic shares are owned by insiders. Comparatively, 4.6% of NanoViricides shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. SummaryImmunic beats NanoViricides on 8 of the 12 factors compared between the two stocks. Get NanoViricides News Delivered to You Automatically Sign up to receive the latest news and ratings for NNVC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NNVC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NNVC vs. The Competition Export to ExcelMetricNanoViricidesPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$22.90M$838.32M$5.76B$21.16BDividend YieldN/A4.84%6.66%3.50%P/E Ratio-1.981.1483.0529.05Price / SalesN/A26.98528.1748.94Price / CashN/A19.5625.7018.29Price / Book2.166.5611.025.30Net Income-$8.29M-$5.07M$3.28B$997.87M7 Day Performance0.35%1.91%0.42%-0.40%1 Month Performance-9.81%10.23%10.90%6.59%1 Year Performance-20.39%23.95%53.91%13.94% NanoViricides Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NNVCNanoViricides0.5413 of 5 stars$1.43+1.8%N/A-28.2%$22.90MN/A-1.9820Short Interest ↓Gap UpIMUXImmunic2.6154 of 5 stars$0.88-7.7%$7.50+755.4%-47.1%$93.72MN/A-0.7170ABOSAcumen Pharmaceuticals2.8653 of 5 stars$1.51-1.3%$7.00+363.6%-50.4%$92.68MN/A-0.6620EPIXESSA Pharma3.5661 of 5 stars$0.78-59.4%$2.00+155.1%-95.7%$91.31MN/A-1.4050Dividend AnnouncementGap DownHigh Trading VolumeCELUCelularity0.7177 of 5 stars$3.84+1.3%$6.00+56.3%-17.2%$90.77M$54.22M-1.45220Earnings ReportGap DownOKYOOKYO Pharma3.0721 of 5 stars$2.43+2.5%$7.00+188.1%+93.3%$89.14MN/A0.007News CoveragePositive NewsShort Interest ↓PLRXPliant Therapeutics4.0797 of 5 stars$1.49+2.8%$8.19+449.5%-87.4%$89.01M$1.58M-0.4490News CoveragePositive NewsLIMNLiminatus PharmaN/A$3.40-0.3%N/AN/A$88.71MN/A0.00N/AGap UpELUTElutia3.3316 of 5 stars$2.39+14.4%$8.00+234.7%-47.3%$88.61M$24.38M-2.25180Positive NewsHigh Trading VolumeENTXEntera Bio1.4152 of 5 stars$1.95+0.5%$10.00+412.8%+18.6%$88.59M$180K-7.5020Positive NewsShort Interest ↓ORMPOramed Pharmaceuticals1.2031 of 5 stars$2.17+1.4%N/A-10.0%$87.75M$1.34M-6.2010Positive NewsHigh Trading Volume Related Companies and Tools Related Companies Immunic Alternatives Acumen Pharmaceuticals Alternatives ESSA Pharma Alternatives Celularity Alternatives OKYO Pharma Alternatives Pliant Therapeutics Alternatives Liminatus Pharma Alternatives Elutia Alternatives Entera Bio Alternatives Oramed Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:NNVC) was last updated on 9/3/2025 by MarketBeat.com Staff From Our PartnersHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe $365M annual revenue crypto play While Bitcoin generates zero operational revenue, one DeFi protocol qu...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NanoViricides, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NanoViricides With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NNVC Stock Alerts